Ulcerative colitis: validity of disease activity indexes and prediction of therapy effect


DOI: https://dx.doi.org/10.18565/therapy.2019.3.72-78

Tkachev A.V., Mkrtchyan L.S., Mazovka K.E.

Department of internal medicine propaedeutics of Rostov State medical University of the Ministry of Healthcare of Russia
Over the past decade, progress has been made in the diagnosis and treatment of ulcerative colitis, but nonetheless the study of treatment-resistant forms of the disease is relevant. Today, there is lack of information about the prediction of these forms of ulcerative colitis. The consequence of this is an insufficient assessment of the severity of the disease, leading to the formation of severe complications. A significant role in determining the severity is played by disease activity indexes.
The aim of the work outlined in this article is to find a way to predict the effectiveness of the basic treatment regimens for ulcerative colitis, which helps prevent complications of the disease, thanks to the early prescription of biological therapy and to evaluate the validity of existing conventional clinical, endoscopic and histological indexes of disease activity.
Material and methods. 70 patients (18–65 years) with relapses of ulcerative colitis were studied.
Results and conclusion. A prospective analysis of a cohort of patients with left-sided and total ulcerative colitis consisting of 70 people made it possible to develop a model for predicting the low effectiveness of treatment with basic drugs. In addition, the study found a high conjugation of clinical indexes Truelove-Witts, Powell-Tuck index, Rakhmilevich’s clinical activity index with a full Mayo Clinic index, and Rakhmilevich’s endoscopic index, endoscopic signs of activity of ulcerative colitis and Mayo Clinic’s histological activity index with a full Mayo Clinic index.
Keywords: index of activity of ulcerative colitis, ulcerative colitis, prognosis
Read entire article

Literature


  1. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br. Med. J. 1955; 2: 1041–48.

  2. Sutherland L.R., Martin F., Greer S. Robinson M., Greenberger N., Saibil F., Martin T., Sparr J., Prokipchuk E., Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterol. 1987; 92(6): 1894–98.

  3. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987; 317(26): 1625–29.

  4. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298: 82–86.

  5. Powell–Tuck J., Bown R.L., Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand. J. Gastroenterol. 1978; 13: 833–37.

  6. Lichtiger S., Present D.H., Kornbluth A., Michelassi F., Hanauer S.B. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994; 330: 1841–45.

  7. Baron J.N., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med. J. 1964; 1: 89–92.

  8. Харитонов А.Г., Кондрашина Э.А., Барановский А.Ю. и соавт. Клинико-иммунологически особенности различных вариантов течения язвенного колита. Клинико-лабораторная диагностика. 2013; 3: 22–26.

  9. Cui D.J. Early aggressive therapy for severe extensive ulcerative colitis. World J. Gastroenterol. 2009; 15(33): 4218–19.

  10. Russo E.A., Harris A.W., Campbell S., Lindsay J., Hart A., Arebi N., Milestone A., Tsai H.H., Walters J., Carpani M., Westaby D., Thillainayagam A., Bansi D., Ghosh S. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centers in England. Aliment. Pharmacol. Ther. 2009; 29: 308–14.

  11. Stange E.F. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J. Crohn’s and Colitis (for the ECCO). 2008; 2(1): 1–23.


About the Autors

Alexander V. Tkachev, MD, professor, Head of the Department of propedeutics of internal diseases of Rostov State medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane. Tel.: +7 (918) 557-11-73. E-mail: tkachev@aaanet.ru
Lilit S. Mkrtchyan, assistant of the Department of propedeutics of internal diseases of Rostov State medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane. Tel.: +7 (928) 113-18-31. E-mail: lilit268@rambler.ru
Karina Y. Mazovka, assistant of the Department of propedeutics of internal diseases of Rostov State medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane. Tel.: +7 (918) 510-07-07. E-mail: k.mazovka@gmail.com


Similar Articles

Back to Content

Бионика Медиа